Theophylline

證據等級: L5

預測適應症: 7 個

Theophylline: From Established Bronchodilator Use to Obstructive Lung Disease (TxGNN-Confirmed) and Six Additional Candidate Indications

One-Sentence Summary

Theophylline is a long-used methylxanthine bronchodilator; this evidence pack does not contain confirmed original-indication or mechanism-of-action data (both are flagged as data gaps), but among the seven indications TxGNN linked to this drug, Obstructive Lung Disease (asthma/COPD) stands out as the only candidate with robust, direct clinical support — 50 clinical trials (including multiple completed Phase 3/4 RCTs, such as a 1,670-patient trial) and 20 publications, reaching the highest evidence tier (L1). The remaining six predicted indications (thrombotic disease, nasal cavity disease, laryngotracheitis, tracheal disease, pharyngitis, acute laryngopharyngitis) range from weak to no supporting evidence and are not considered actionable at this time.

Quick Overview

Item	Content
Original Indication	Not available — no SAHPRA-registered product on file for theophylline in this data set (data gap; original indication/MOA not confirmed)
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.48%
Evidence Level	L1
South Africa Market Status	Not marketed (未上市)
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as a Blocking/High-severity data gap — DG002). Based on the mechanistic rationale accompanying the TxGNN prediction and the supporting literature itself, theophylline is a classic methylxanthine that relaxes airway smooth muscle through phosphodiesterase (PDE3/4) inhibition and adenosine-receptor antagonism, with additional mild anti-inflammatory activity at lower plasma concentrations.

This mechanism maps directly onto the pathophysiology of obstructive airway disease (asthma and COPD), where bronchospasm and airway inflammation are the core problems. Several of the literature items retrieved for this candidate (e.g., PMID 23672674, PMID 14988770) explicitly describe theophylline as having been used to treat asthma and COPD for over 80 years — meaning this “predicted” indication is, in practice, a well-established therapeutic use rather than a novel repurposing hypothesis. In that sense, this result is best read as a positive-control confirmation of the TxGNN model (it correctly recovered a known drug-disease relationship) rather than a genuinely new signal, which is an important distinction for interpreting the “Proceed with Guardrails” recommendation below: the guardrails relate mainly to South African regulatory/safety documentation gaps, not to scientific plausibility.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02261727	Phase 4	Completed	1,670	TASCS trial — low-dose theophylline ± low-dose prednisone vs. placebo for reducing COPD exacerbations and improving quality of life over 48 weeks
NCT00252785	Phase 3	Completed	340	Symbicort Turbuhaler vs. Pulmicort Turbuhaler + Theolong (theophylline) 200 mg BID in Japanese asthma patients
NCT03984188	Phase 3	Completed	100	Low-dose theophylline for management of biomass-fuel-associated COPD
NCT03015090	N/A	Completed	110	CYP1A2 gene polymorphisms and theophylline metabolism in Han and Uygur COPD patients
NCT02001935	N/A	Completed	102	CYP1A2/CYP2E1 polymorphisms and theophylline metabolism in COPD
NCT02023554	N/A	Completed	40	PK interaction study — effect of azithromycin on steady-state theophylline plasma levels
NCT00756418	Phase 4	Completed	84	Randomized comparison of montelukast vs. theophylline added to inhaled corticosteroid in pediatric asthma
NCT00299858	Phase 2/3	Completed	24	Theophylline’s effect on exercise capacity and lung function in COPD patients on long-acting bronchodilators
NCT00241631	Phase 2	Completed	49	RCT of theophylline + fluticasone on induced sputum cells in COPD
NCT00671151	N/A	Completed	35	Molecular mechanisms of COPD exacerbations and modulating effect of low-dose theophylline (NF-κB, HDAC pathways)

Note: No South African National Clinical Trials Register (SANCTR) or Pan African Clinical Trials Registry (PACTR) entries were found in this evidence pack; all listed trials are drawn from ClinicalTrials.gov.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
7982769	1994	RCT	Israel Journal of Medical Sciences	Double-blind crossover RCT showing theophylline improves exercise and bronchial reactivity in COPD without significant neuropsychological impairment
1729064	1992	RCT	Chest	Double-blind, four-phase crossover RCT: theophylline and salbutamol both improve pulmonary function in irreversible COPD
14988770	2004	Review	Drugs of Today	Comprehensive review of theophylline’s mechanism of action and role in asthma/COPD treatment
23672674	2013	Review	American Journal of Respiratory and Critical Care Medicine	Landmark review (Barnes) — theophylline used for airway disease for 80+ years; anti-inflammatory effects at low concentrations via PDE inhibition
7783821	1995	Review	Netherlands Journal of Medicine	Reviews the clinical positioning of theophylline in asthma and COPD treatment
8513541	1993	Review	Cleveland Clinic Journal of Medicine	Discusses controversy around theophylline toxicity risk vs. benefit in ambulatory COPD management
3534060	1986	Clinical Study	Journal of Allergy and Clinical Immunology	Theophylline improves global cardiac function and reduces dyspnea in COPD
8518774	1993	Cohort	Monaldi Archives for Chest Disease	Theophylline reduces hyperinflation/trapped gas in chronic airflow limitation
2877017	1986	Clinical Review	Journal of Allergy and Clinical Immunology	Evidence that maintenance theophylline therapy produces measurable patient improvement in COPD
9756187	1998	Clinical Review	Clinical and Experimental Allergy	Describes anti-inflammatory/immunomodulatory activity of theophylline beyond bronchodilation in COPD

South Africa Market Information

Theophylline has no active SAHPRA registrations in this data set (0 licenses on file; market status: Not marketed). No product name, dosage form, or SAHPRA-approved indication text is available for South Africa at this time.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Outstanding data gap (Blocking): TFDA/SAHPRA-equivalent package insert warnings and contraindications for theophylline have not yet been retrieved for this evidence pack. This must be resolved before any Stage 1 safety screening can be completed, given theophylline’s known narrow therapeutic index and extensive CYP1A2/CYP3A4-mediated drug interaction profile referenced throughout the literature above (e.g., azithromycin PK interaction, CYP1A2/CYP2E1 polymorphism studies).

Other Predicted Indications (Lower Evidence — Not Actionable)

This evidence pack included six additional TxGNN-predicted indications for theophylline, all ranked by raw model score higher than or close to Obstructive Lung Disease but with materially weaker supporting evidence:

Rank	Disease	TxGNN Score	Evidence Level	Recommendation	Notes
1	Thrombotic disease	99.62%	L5	Hold	19 publications retrieved, but nearly all are unrelated to theophylline (ticlopidine PK, platelet biomarker methodology, cerebral edema); only 1 addresses theophylline directly (a biosensor detection paper, not clinical efficacy)
2	Nasal cavity disease	99.53%	L2	Research Question	One completed Phase 2 trial (SCENT, n=27) on nasal theophylline irrigation for post-viral smell loss, plus one supportive RCT on allergic rhinitis nasal challenge — promising but small, early-stage
3	Laryngotracheitis	99.51%	L5	Hold	No clinical trials or literature identified
4	Tracheal disease	99.49%	L3	Research Question	Strong basic pharmacology (tracheal smooth muscle relaxation) and a veterinary retrospective study on tracheal collapse, but no prospective human clinical trial
6	Pharyngitis	99.46%	L5	Hold	11 publications retrieved, mostly concerning unrelated macrolide antibiotics for pediatric pharyngitis; no direct theophylline efficacy evidence
7	Acute laryngopharyngitis	99.35%	L5	Hold	No clinical trials or literature identified

These candidates are documented here for completeness but require substantially more evidence generation (or should be deprioritized) before further evaluation.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The Obstructive Lung Disease candidate is supported by an extensive and mature evidence base — 50 clinical trials (including large completed Phase 3/4 RCTs) and 20 publications spanning four decades — reaching evidence tier L1. However, this is functionally a confirmation of theophylline’s long-established bronchodilator role rather than a novel repurposing opportunity, and two Blocking/High-severity data gaps (SAHPRA/TFDA-equivalent safety labeling, and confirmed mechanism-of-action documentation) remain unresolved, and the drug has zero current SAHPRA registrations in South Africa.

To proceed, the following is needed:

Retrieval of SAHPRA-approved Professional Information (PI) — warnings, contraindications, and drug interaction data (currently a Blocking data gap, DG001)
Confirmed mechanism-of-action documentation from DrugBank or equivalent source (High-severity data gap, DG002)
Confirmation of theophylline’s regulatory pathway/status for potential SAHPRA registration or Section 21-type access in South Africa, given it is currently unmarketed
For the Nasal Cavity Disease and Tracheal Disease candidates: monitor for larger prospective human trials before elevating beyond “Research Question” status
For Thrombotic Disease, Laryngotracheitis, Pharyngitis, and Acute Laryngopharyngitis: no further action recommended unless new trial or literature evidence emerges
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.